Clinical risk factors for the development of tardive dyskinesia

Tardive dyskinesia (TD) is a severe condition that can affect almost 1 out of 4 patients on current or previous antipsychotic treatment, including both first-generation antipsychotics (FGAs) and second-generation antipsychotics (SGAs). While two novel vesicular monoamine transporter inhibitors, deutetrabenazine and valbenazine, have shown acute efficacy for TD, the majority of patients do not remit, and TD appears to recur once treatment is withdrawn. Hence, prevention of TD remains a crucial goal.

Source: Journal of the Neurological Sciences - February 5, 2018 Category: Neurology Authors: Marco Solmi, Giorgio Pigato, John M. Kane, Christoph U. Correll Tags: Review Article Source Type: research